Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Xynomic Pharma to List on Nasdaq via Reverse-Merger at $450 Million Valuation

publication date: Sep 13, 2018

Xynomic Pharmaceuticals, a US-China clinical-stage oncology company, will be merged into Bison Capital Acquisition in a reverse merger that values Xynomic at $450 million. Initially, Xynomic shareholders will receive $350 million in Bison shares, with another $100 million available if the company meets specified milestones. The company said a NASDAQ listing will improve its access to capital. In its two-year history, Xynomic has in-licensed two novel oral small-molecule cancer treatment candidates. Bison, a special purpose vehicle, will change its name to Xynomic Pharmaceuticals Holding. More details....

Stock Symbol: (NSDQ: BCAC)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.